The drugmaker is following in the footsteps of Johnson & Johnson and Eli Lilly in filing suit to force through controversial reforms to the drug discount program, against the wishes of federal regulators.
The drugmaker is following in the footsteps of Johnson & Johnson and Eli Lilly in filing suit to force through controversial reforms to the drug discount program, against the wishes of federal regulators.